Nevertheless, ILC1s are potent producers of the type 1 cytokine IFNγ, which has well-established anti-tumoural functions [2], and patients with cancer that express a high IFNγ-related signature are associated with improved prognosis and response to immunotherapies including immune checkpoint inhibitors [19]. This evidence concerns the gene IFNG and cancer.